Graphene could be a novel anti-cancer therapeutic strategy

27th February 2015

Graphene could potentially be used as a strategy for tackling cancer stem cells, a new study has found.

Research from the University of Manchester found that the drug could be used to prevent or treat a broad range of cancers by using a non-toxic material. 

In the Oncotarget journal, a team of researchers led by professor Michael Lisanti and Dr Aravind Vijayaraghavan showed that graphene oxide can act as an anti-cancer agent that can judiciously target cancer stem cells (CSCs).

In combination with existing treatments, graphene could lead to tumour shrinkage, prevent cancer spreading and stop it from recurring after treatment is completed. 

Professor Lisanti, the Director of the Manchester Centre for Cellular Metabolism within the University's Institute of Cancer Sciences, said: “Cancer stem cells possess the ability to give rise to many different tumour cell types.” 

Mr Lisanti explained that the cells are responsible for the spread of cancer within the body, which is accountable for around 90 per cent of cancer deaths.

Posted by Phillip Briggs 

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Cancer

© Spire Healthcare Group plc (2016)